Current and emerging pharmacotherapy for emergency management of preeclampsia

References

• Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta. 2002;23(5):359–372.
   PubMed Web of Science ®Google Scholar
• Kweider N, Wruck CJ, Rath W. New insights into the pathogenesis of preeclampsia - the role of nrf2 activators and their potential therapeutic impact. Geburtshilfe Frauenheilkd. 2013;73(12):1236–1240.
   PubMed Web of Science ®Google Scholar
• Mol BBWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387(10022):999–1011.
   PubMed Web of Science ®Google Scholar
• Lowe SA, Bowyer L, Lust K, et al. The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015; 55(5):e1–29.
   Web of Science ®Google Scholar
• World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: Author; 2011.
   Google Scholar
• Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104.
   PubMed Web of Science ®Google Scholar
• Magee LA, Von Dadelszen P, Singer J, et al. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of hypertension in pregnancy study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763–776.
   PubMed Web of Science ®Google Scholar
• Magee LA, Von Dadelszen P, Singer J, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study). Hypertension. 2016;68(5):1153–1159.
   PubMed Web of Science ®Google Scholar
• Fenton C, Hobson SR, Wallace EM, et al. Future therapies for pre-eclampsia: beyond treading water. Aust N Z J Obstet Gynaecol. 2014;54(1):3–8.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–495.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–622.
   PubMed Web of Science ®Google Scholar
• Hofmeyr GJ, Lawrie TA, Án A, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014;24(6):CD001059.
   Google Scholar
• Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118:1.
   PubMed Web of Science ®Google Scholar
• Martin JN, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246–254.
   PubMed Web of Science ®Google Scholar
• Rey E, LeLorier J, Burgess E, et al. Report of the Canadian hypertension society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997;157(9):1245–1254.
   PubMed Web of Science ®Google Scholar
• Redman CWG. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97(23):1967–1969.
   PubMed Web of Science ®Google Scholar
• Easterling TR. Pharmacological management of hypertension in pregnancy. Semin Perinatol. 2014;38(8):487–495.
   PubMed Web of Science ®Google Scholar
• Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br J Obstet Gynaecol. 1977;84(6):419–426.
   Google Scholar
• DeMuth GW, Ackerman SH. Alpha-methyldopa and depression: a clinical study and review of the literature. Am J Psychiatry. 1983;140(5):534–538.
   PubMed Web of Science ®Google Scholar
• Redman CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976;2(7989):753–756.
   PubMed Web of Science ®Google Scholar
• Weitz C, Khouzami V, Maxwell K, et al. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987;25(1):35–40.
   PubMed Web of Science ®Google Scholar
• Redman CW, Ounsted MK. Safety for the child of drug treatment for hypertension in pregnancy. Lancet. 1982;1(8283):1237.
   PubMed Web of Science ®Google Scholar
• Xie RH, Guo Y, Krewski D, et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):281–285.
   PubMed Web of Science ®Google Scholar
• El-Qarmalawi AM, Morsy AH, Al-Fadly A, et al. Labetalol vs. Int J Gynecol Obstet. 1995;49(2):125–130.
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P, Singer J, et al. Control of hypertension in pregnancy study randomised controlled trial—are the results dependent on the choice of labetalol or methyldopa? BJOG. 2016;123(7):1135–1141.
   PubMed Web of Science ®Google Scholar
• Vermillion ST, Scardo JA, Newman RB, et al. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181(4):858–861.
   PubMed Web of Science ®Google Scholar
• Walker JJ, Greer I, Calder AA. Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgr Med J. 1983;59:168–170.
   PubMed Web of Science ®Google Scholar
• Mabie WC, Gonzalez AR, Sibai BM, et al. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70:328–333.
   PubMed Web of Science ®Google Scholar
• Klarr J, Bhatt-Mehta V, Donn S. Neonatal adrenergic blockade following single dose maternal labetalol administration. Am J Perinatol. 1994;11(2):91–93.
   PubMed Web of Science ®Google Scholar
• Moore MP, Redman CWG. The treatment of hypertension in pregnancy. Curr Med Res Opin. 1982;90(2):1499–1504.
   Google Scholar
• Petersen KM, Jimenez-Solem E, Andersen JT, et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185.
   PubMed Web of Science ®Google Scholar
• Bulpitt CJ, Lewis PJ, Swiet MD. How obstetricians manage hypertension in pregnancy. Br Med J. 1978;1(6113):626–629.
   PubMedGoogle Scholar
• Pickles CJ, Symonds EM, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96(1):38–43.
   PubMedGoogle Scholar
• Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992;99(12):964–968.
   PubMedGoogle Scholar
• Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;6(2):CD002252.
   Google Scholar
• Xie RH, Guo Y, Krewski D, et al. Beta-Blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG. 2014;121(9):1090–1096.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Hernandez-Diaz S, Huybrechts KF, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a medicaid population. Hypertension. 2012;60(4):913–920.
   PubMed Web of Science ®Google Scholar
• Cruickshank DJ, Robertson AA, Campbell DM, et al. Does labetalol influence the development of proteinuria in pregnancy hypertension? A randomised controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;45(1):47–51.
   PubMed Web of Science ®Google Scholar
• Ismail AAA, Medhat I, Tawfic TAS, et al. Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia. Int J Gynecol Obstet. 1993;40(1):39–43.
   PubMed Web of Science ®Google Scholar
• Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. J Clin Hypertens. 1986;2(3):28–37.
   Google Scholar
• Jayawardana J, Lekamge N. A comparison of nifedipine with methyldopa in pregnancy induced hypertension. Ceylon Med J. 1994;39(2):87–90.
   PubMedGoogle Scholar
• Firoz T, Magee LA, MacDonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;1(1):1210–1218.
   Google Scholar
• Melchiorre K, Sutherland GR, Watt-Coote I, et al. Severe myocardial impairment and chamber dysfunction in preterm preeclampsia. Hypertens Pregnancy. 2012;31(4):454–471.
   PubMed Web of Science ®Google Scholar
• Cong J, Fan T, Yang X, et al. Maternal cardiac remodeling and dysfunction in preeclampsia: a three-dimensional speckle-tracking echocardiography study. Int J Cardiovasc Imaging. 2015;31(7):1361–1368.
   PubMed Web of Science ®Google Scholar
• Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 2011;23(6):440–447.
   PubMed Web of Science ®Google Scholar
• Bhorat I, Naidoo DP, Moodley J. Maternal cardiac haemodynamics in severe pre-eclampsia complicated by acute pulmonary oedema. J Matern Fetal Neonatal Med. 2017;30(23):2769–2777.
   PubMed Web of Science ®Google Scholar
• Shi DD, Yang FZ, Zhou L, et al. Oral nifedipine vs. J Clin Pharm Ther. 2016;41(6):657–661.
   PubMed Web of Science ®Google Scholar
• Brown MA, McCowan LM, North RA, et al. Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian society for the study of hypertension in pregnancy. Med J Aust. 1997;166(12):640–643.
   PubMedGoogle Scholar
• Webster LM, Myers JE, Nelson-Piercy C, et al. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension. 2017;70(5):915–922.
   PubMed Web of Science ®Google Scholar
• Koontz SL, Friedman SA, Schwartz ML. Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine. Am J Obstet Gynecol. 2004;190(6):1773–1776.
   PubMed Web of Science ®Google Scholar
• Hodges R, Barkehall-Thomas A, Tippett C. Maternal hypoxia associated with nifedipine for threatened preterm labour. BJOG. 2004;111(4):380–381.
   PubMed Web of Science ®Google Scholar
• Ben Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. BJOG. 1994;101(3):262–263.
   Google Scholar
• Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol. 1989;161(1):35–36.
   PubMed Web of Science ®Google Scholar
• Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 2005;193(1):153–163.
   PubMed Web of Science ®Google Scholar
• Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–960.
   PubMed Web of Science ®Google Scholar
• NICE. Hypertension in pregnancy: diagnosis and management, 2010. Available from: https://www.nice.org.uk/guidance/cg107 [Accessed 22 January 2019].
   Google Scholar
• Crozier TM, Wallace EM, Parkin WG. Haemodynamic assessment in pregnancy and pre-eclampsia: a Guytonian approach. Pregnancy Hypertens. 2015;5(2):177–181.
   PubMed Web of Science ®Google Scholar
• Walker JJ. Severe pre-eclampsia and eclampsia. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(1):57–71.
   PubMed Web of Science ®Google Scholar
• Rezaei Z, Sharbaf FR, Pourmojieb M, et al. Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. Acta Med Iran. 2011;49(11):701–706.
   PubMedGoogle Scholar
• Aali BS, Nejad SS. Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstet Gynecol Scand. 2002;81(1):25–30.
   PubMed Web of Science ®Google Scholar
• Walss Rodriguez RJ, Flores Padilla LM. Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents. Ginecol Obs Mex. 1993;61:76–79.
   PubMedGoogle Scholar
• Voto LS, Zin C, Neira J, et al. Ketanserin versus alpha-methyldopa in the treatment of hypertension during pregnancy: a preliminary report. J Cardiovasc Pharmacol. 1987;10(3):101–103.
   Google Scholar
• Weiner CP, Socol ML, Vaisrub N. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist. Am J Obstet Gynecol. 1984;149(5):496–500.
   PubMed Web of Science ®Google Scholar
• Rossouw HJ, Howarth G, Odendaal HJ. Ketanserin and hydralazine in hypertension in pregnancy - A randomised double-blind trial. S Afr Med J. 1995;85(6):525–528.
   PubMed Web of Science ®Google Scholar
• Bijvank SWN, Visser W, Duvekot JJ, et al. Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;1889:106–111.
   Google Scholar
• Hennessy A, Thornton CE, Makris A, et al. A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial. Aust N Z J Obstet Gynaecol. 2007;47(4):279–285.
   PubMed Web of Science ®Google Scholar
• Michael CA. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. ANZ J Obstet Gynaecol. 1986;26(1):26–29.
   Google Scholar
• Hall DR, Odendaal HJ, Steyn DW, et al. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. BJOG. 2000;107(6):759–765.
   PubMedGoogle Scholar
• Diemunsch P, Garcia V, Lyons G, et al. Urapidil versus nicardipine in preeclamptic toxaemia: a randomised feasibility study. Eur J Anaesthesiol. 2015;32(11):822–823.
   PubMed Web of Science ®Google Scholar
• Jannet D, Carbonne B, Sebban E, et al. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol. 1994;84(3):354–359.
   PubMed Web of Science ®Google Scholar
• Montan S, Anandakumar C, Arulkumaran S, et al. Randomised controlled trial of methyldopa and isradipine in preeclampsia - effects on uteroplacental and fetal hemodynamics. J Perinat Med. 1996;24(2):177–184.
   PubMed Web of Science ®Google Scholar
• Fletcher H, Roberts G, Mullings A, et al. An open trial comparing isradipine with hydralazine and methyldopa in the treatment of patients with severe pre-eclampsia. J Obstet Gynaecol (Lahore). 1999;19(3):235–238.
   Google Scholar
• Vargas-Ayala G, Salmeron Perez G, Sanchez Garcia AR, et al. Efficancy of isosorbide in aerosol in the management of hypertensive crisis of severe preeclampsia. Ginecol Obstet Mex. 1998;66:316–319.
   PubMedGoogle Scholar
• Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, et al. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol. 2008;35(5–6):580–585.
   PubMed Web of Science ®Google Scholar
• Tabacova S, Little R, Tsong Y, et al. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf. 2003;12(8):633–646.
   PubMed Web of Science ®Google Scholar
• Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80(3):429–432.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Churchill D, Beevers M, et al. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet. 1997;350(9089):1446–1447.
   PubMed Web of Science ®Google Scholar
• Velázquez-Armenta EY, Han JY, Choi JS, et al. Angiotensin II receptor blockers in pregnancy: a case report and systematic review of the literature. Hypertens Pregnancy. 2007;26(1):51–66.
   PubMed Web of Science ®Google Scholar
• Gallery EDM, Saunders DM, Hunyor SN, et al. Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J. 1979;1(6178):1591–1594.
   PubMedGoogle Scholar
• Gallery ED, Ross MR, Gyory AZ, et al. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. Br Med J (Clin Res Ed). 1985;291(6495):563–566.
   PubMedGoogle Scholar
• Livingstone I, Craswell PW, Bevan EB, et al. Propranolol in pregnancy three year prospective study. Hypertens Pregnancy. 1983;2(2):341–350.
   Web of Science ®Google Scholar
• Oumachigui A, Verghese M, Balachander J. A comparative evaluation of metoprolol and methyldopa in the management of pregnancy induced hypertension. Indian Heart J. 1992;44(1):39–41.
   PubMedGoogle Scholar
• Wichman K, Ryden G, Karlberg BE. A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Invest. 1984;44(169):90–95.
   Google Scholar
• Lydakis C, Lip GYH, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541–547.
   PubMed Web of Science ®Google Scholar
• Ellenbogen A, Jaschevatzky O, Davidson A, et al. Management of pregnancy-induced hypertension with pindolol-comparative study with methyldopa. Int J Gynecol Obstet. 1986;24(1):3–7.
   PubMed Web of Science ®Google Scholar
• Paran E, Holzberg G, Mazor M, et al. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther. 1995;33(2):119–123.
   PubMed Web of Science ®Google Scholar
• The Magpie Trial Collaborative Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Lancet 2002;369:1877–1890
   Google Scholar
• Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG. 2006;113(2):144–151.
   PubMed Web of Science ®Google Scholar
• Hutton JD, James DK, Stirrat GM, et al. Management of severe pre‐eclampsia and eclampsia by UK consultants. BJOG. 2018;99(7):554–556. 25.
   Google Scholar
• ACOG guidelines: hypertension in pregnancy. American college of obstetricians and gynecologists. Task Force on Hypertension in Pregnancy. 2013.
   Google Scholar
• Magee LA, Bc V, Helewa M, et al. SOGC clinical practice guidelines diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obs Gynaecol Can. 2014;36(5):416–438
   PubMedGoogle Scholar
• Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;10(11):CD000025.
   Google Scholar
• Smyth RMD, Spark P, Armstrong N, et al. Magpie trial in the UK: methods and additional data for women and children at 2 years following pregnancy complicated by pre-eclampsia. BMC Pregnancy Childbirth. 2009;14(9):5.
   Google Scholar
• Duley L, Farrell B, Armstrong N, et al. The magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG. 2007;114(3):300–309.
   PubMed Web of Science ®Google Scholar
• Duley L, Farrell B, Armstrong N, et al. The magpie trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG. 2007;114(3):289–299.
   PubMed Web of Science ®Google Scholar
• Maternal deaths in Australia 2008–2012 [Internet]. 2012. Available from: https://www.aihw.gov.au/reports/mothers-babies/maternal-deaths-in-australia-2008-2012/contents/table-of-contents [Accessed 22 January 2019].
   Google Scholar
• Crowther CA, Middleton PF, Voysey M, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLoS Med. 2017; 14(10):e1002398
   PubMed Web of Science ®Google Scholar
• Jacquemyn Y, Zecic A, Van Laere D, et al. The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection. Arch Gynecol Obstet. 2015;291(5):969–975.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Mercer BM, Schiff E, et al. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171(3):818–822.
   PubMed Web of Science ®Google Scholar
• Oláh KS, Redman CWG, Gee H. Management of severe, early pre-eclampsia: is conservative management justified? Eur J Obstet Gynecol Reprod Biol. 1993;51(3):175–180.
   PubMed Web of Science ®Google Scholar
• Sarsam DS, Shamden M, Al Wazan R, et al. Expectant versus aggressive management in severe preeclampsia remote from term. Singapore Med J. 2008;49(9):698–703.
   PubMed Web of Science ®Google Scholar
• Schwartz RB, Feske SK, Polak JF, et al. Preeclampsia-Eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology. 2000;217(2):371–376.
   PubMed Web of Science ®Google Scholar
• Teela KC, Ferguson RM, Donnay FA, et al. The PIERS trial: hope for averting deaths from pre-eclampsia. Lancet. 2011;9761(377):185–186.
   Google Scholar
• Ukah UV, Payne B, Karjalainen H, et al. Temporal and external validation of the fullPIERS model for the rpediction of adverse maternal outcomes in women with preeclampsia. Pregnancy Hypertens. 2019;15:42–50.
   PubMedGoogle Scholar
• Hobson SR, Gurusinghe S, Lim R, et al. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. J Pineal Res. 2018;65(3):e12508.
   PubMed Web of Science ®Google Scholar
• Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366(9499):1797–1803.
   PubMed Web of Science ®Google Scholar
• Nisell H, Lintu H, Lunell NO, et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol. 1995;102(11):876–881.
   PubMedGoogle Scholar
• Bellamy L, Casas J-P, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
   PubMed Web of Science ®Google Scholar
• Agatisa PK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. AJP Hear Circ Physiol. 2003;286(4):1389–1393.
   Web of Science ®Google Scholar
• Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis. 2008;2(4):249–259.
   PubMedGoogle Scholar
• Cain MA, Salemi JL, Tanner JP, et al. Pregnancy as a window to future health: maternal placental syndromes and short-term cardiovascular outcomes. Am J Obstet Gynecol. 2016;215(4):484.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet. 1999;354(9181):788–789.
   PubMed Web of Science ®Google Scholar
• Trapani A, Gonçalves LF, Trapani TF, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment. Obstet Gynecol. 2016;128(2):253–259.
   PubMed Web of Science ®Google Scholar
• Trapani A, Gonçalves LF, Trapani TF. Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices. Ultrasound Obstet Gynecol. 2016;48(1):61–65.
   PubMed Web of Science ®Google Scholar
• Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009;28(4):369–382.
   PubMed Web of Science ®Google Scholar
• Sharp A, Cornforth C, Jackson R, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Heal. 2018;2(2):93–102.
   Web of Science ®Google Scholar
• Groom KM, Ganzevoort W, Alfirevic Z, et al. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol. 2018;52(3):295–296.
   PubMed Web of Science ®Google Scholar
• Miller SL, Loose JM, Jenkin G, et al. The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol. 2009;200(1):102–107.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Longo M, Piccinini F, et al. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig. 1999;6(4):202–207.
   PubMedGoogle Scholar
• Staff AC, Berge L, Haugen G, et al. Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. Acta Obstet Gynecol Scand. 2004;83(1):103–107.
   PubMed Web of Science ®Google Scholar
• Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011;342:d2901.
   PubMed Web of Science ®Google Scholar
• Walker JD. NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. Diabet Med. 2008;25(9):1025–1027.
   PubMed Web of Science ®Google Scholar
• Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017;217:3282–3302.
   Web of Science ®Google Scholar
• Alqudah A, McKinley MC, McNally R, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018;35(2):160–172.
   PubMed Web of Science ®Google Scholar
• Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222(3):222–235.
   PubMed Web of Science ®Google Scholar
• Livingston JC, Chin R, Haddad B. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol. 2000;183(6):1554–1557.
   PubMed Web of Science ®Google Scholar
• Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354(9181):810–816.
   PubMed Web of Science ®Google Scholar
• Beazley D, Ahokas R, Livingston J, et al. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2005;192(2):520–521.
   PubMed Web of Science ®Google Scholar
• Chappell LC, Seed PT, Kelly FJ, et al. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol. 2002;187(3):777–784.
   PubMed Web of Science ®Google Scholar
• McCance DR, Holmes VA, Maresh MJA, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet. 2010;376(6736):259–266.
   PubMedGoogle Scholar
• Kalpdev A, Saha SC, Dhawan V. Vitamin C and e supplementation does not reduce the risk of superimposed PE in pregnancy. Hypertens Pregnancy. 2011;30(4):447–456.
   PubMed Web of Science ®Google Scholar
• Rayman MP, Bath SC, Westaway J, et al. Selenium status in UK pregnant women and its relationship with hypertensive conditions of pregnancy. Br J Nutr. 2015;113(2):249–258.
   PubMed Web of Science ®Google Scholar
• Vanderlelie J, Venardos K, Perkins AV. Selenium deficiency as a model of experimental pre-eclampsia in rats. Reproduction. 2004;128(5):635–641.
   PubMed Web of Science ®Google Scholar
• Lymbury RS, Marino MJ, Perkins AV. Effect of dietary selenium on the progression of heart failure in the ageing spontaneously hypertensive rat. Mol Nutr Food Res. 2010;54(10):1436–1444.
   PubMed Web of Science ®Google Scholar
• Kiełczykowska M, Kocot J, Lewandowska A, et al. The protective influence of selenium on oxidant disturbances in brain of rats exposed to lithium. Physiol Res. 2015;64(5):739–746.
   PubMed Web of Science ®Google Scholar
• Rayman MP, Searle E, Kelly L, et al. Effect of selenium on markers of risk of pre-eclampsia in UK pregnant women: a randomised, controlled pilot trial. Br J Nutr. 2014;112(1):99–111.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Rezai H, Broadway-Stringer S. Evidence-based revised view of the pathophysiology of preeclampsia. Adv Exp Med Biol. 2017;956:355–374.
   PubMed Web of Science ®Google Scholar
• Tara F, Maamouri G, Rayman MP, et al. Selenium supplementation and the incidence of preeclampsia in pregnant Iranian women: a randomized, double-blind, placebo-controlled pilot trial. Taiwan J Obstet Gynecol. 2010;49(2):181–187.
   PubMed Web of Science ®Google Scholar
• Han L, Zhou S. Selenium supplement in the prevention of pregnancy induced hypertension. Chin Med J (Engl). 1994;107(11):870–871.
   PubMed Web of Science ®Google Scholar
• Oldfield JE. The two faces of selenium. J Nutr. 1987;117(12):2002–2008.
   PubMed Web of Science ®Google Scholar
• Vinceti M, Wei E, Malagoli C, et al. Adverse health effects of selenium in humans. Rev Environ Health. 2001;16:233.
   PubMedGoogle Scholar
• Usami M, Ohno Y. Teratogenic effects of selenium compounds on cultured postimplantation rat embryos. Teratog Carcinog Mutagen. 1996;16(1):27–36.
   PubMedGoogle Scholar
• Yang X, Yu X, Fu H, et al. Different levels of prenatal zinc and selenium had different effects on neonatal neurobehavioral development. Neurotoxicology. 2013;37:35–39.
   PubMed Web of Science ®Google Scholar
• Parrish RM, Martin NJ, Lamarca BB, et al. Randomized, placebo controlled, double blind trial evaluating early pregnancy phytonutrient supplementation in the prevention of preeclampsia. J Perinatol. 2013;33(8):593–599.
   PubMed Web of Science ®Google Scholar
• Ding J, Kang Y, Fan Y, et al. Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia. Endocr Connect. 2017;6(8):595–600.
   PubMed Web of Science ®Google Scholar
• Gurusinghe S, Cox AG, Rahman R, et al. Resveratrol mitigates trophoblast and endothelial dysfunction partly via activation of nuclear factor erythroid 2-related factor-2. Placenta. 2017;60:74–85.
   PubMed Web of Science ®Google Scholar
• Bouchlariotou S, Liakopoulos V, Giannopoulou M, et al. Melatonin secretion is impaired in women with preeclampsia and an abnormal circadian blood pressure rhythm. Ren Fail. 2014;36(7):1001–1007.
   PubMed Web of Science ®Google Scholar
• Hobson SR, Mockler JC, Lim R, et al. Melatonin for treating pre-eclampsia. Cochrane Database Syst Rev. 2016.
   Google Scholar
• Girouard H, Chulak C, Lejossec M, et al. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J Hypertens. 2001;19(8):1369–1377.
   PubMed Web of Science ®Google Scholar
• Hu ZP, Fang XL, Fang N, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits. J Pineal Res. 2013;55(4):388–398.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang C, Hou Y, et al. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur Rev Med Pharmacol Sci. 2013;17(18):2449–2456.
   PubMed Web of Science ®Google Scholar
• Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012;57(3):699–705.
   PubMed Web of Science ®Google Scholar
• Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114–2123.
   PubMed Web of Science ®Google Scholar
• Onda K, Tong S, Beard S, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69(3):457–468.
   PubMed Web of Science ®Google Scholar
• Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17(1):89–93.
   PubMed Web of Science ®Google Scholar
• Cluver CA, Walker SP, Mol BW, et al. Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open. 2015;5(10):e008211.
   PubMed Web of Science ®Google Scholar
• Cluver CA, Hannan NJ, van Papendorp, E, et al. Esomeprazole to treat women with preterm preeclampsia: a randomised placebo controlled trial. Am J Obstet Gynecol. 2018;219(4):388–e1
   PubMed Web of Science ®Google Scholar
• Myers JE, Kenny LC, McCowan LM, et al. SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013;120:1215–1223.
   PubMed Web of Science ®Google Scholar
• Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 2013;53:532–539.
   PubMed Web of Science ®Google Scholar
• Saleh L, Verdonk K, Danser AHJ, et al. The sFlt-1/PlGF ration associated with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort. Eur J Obstet Gynecol. 2016;199:121–126.
   PubMed Web of Science ®Google Scholar
• Rana S, Salahuddin S, Mueller A, et al. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018;13:100–106.
   PubMed Web of Science ®Google Scholar
• Dragan I, Georgiou T, PRodan N, et al. Screening for preeclampsia using sFLt-1/PlGF ration cut-off of 38 at 30–37 weeks’ gestation. Ultrasound Obstetrics Gynecology. 2017;49::73–77.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Cerdeira AS, Redman C, et al. Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placental growth factor ration in the prediction of preeclampsia. The SaPPPhirE study. Hypertens. 2018;71:306–331.
   PubMed Web of Science ®Google Scholar
• D’Antona D, Reis FM, Benedetto C, et al. Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders. J Endocrinol. 2000.
   PubMed Web of Science ®Google Scholar
• Lim R, Acharya R, Delpachitra P, et al. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol. 2015;212(1):86e1–12.
   Web of Science ®Google Scholar
• Lim R, Adhikari S, Gurusinghe S, et al. Inhibition of activin A signaling in a mouse model of preeclampsia. Placenta. 2015;36:926–931.
   PubMedGoogle Scholar
• Hobson SR, Acharya R, Lim R, et al. Role of activin A in the pathogenesis of endothelial cell dysfunction preeclampsia. Pregnancy Hypertens. 2016;6:130–133.
   PubMed Web of Science ®Google Scholar
• Chen B, Tuuli MG, Longtime MS, et al. Pomegranate juice and punicalagin attentuate oxidative stress and apoptosis in human placenta and in human placental trophoblast. Am J Physiol Endocrinol Metab. 2012;302:E1142–E1152.
   PubMed Web of Science ®Google Scholar